Ohcanbohtosat - David Floch

  • Čájehuvvo 1 - 3 / 3
Aiddostahte ozu
  1. 1
    Pharmacokinetic and Pharmacodynamic Properties of Canakinumab, a Human Anti-Interleukin-1β Monoclonal Antibody

    Pharmacokinetic and Pharmacodynamic Properties of Canakinumab, a Human Anti-Interleukin-1β Monoclonal Antibody Dahkki Abhijit Chakraborty, Stacey Tannenbaum, Christiane Rordorf, Philip J. Lowe, David Floch, Hermann Gram, Sandip Kumar Roy

    Almmustuhtton 2012
    Viečča ollesdeavstta Viečča ollesdeavstta
    Revisão
    Lasit oiddohiidda
    Furkejuvvon:
  2. 2
    Pharmacokinetics, pharmacodynamics and safety of <scp>QGE</scp>031 (ligelizumab), a novel high‐affinity anti‐IgE antibody, in atopic subjects

    Pharmacokinetics, pharmacodynamics and safety of <scp>QGE</scp>031 (ligelizumab), a novel high‐affinity anti‐IgE antibody, in atopic subjects Dahkki Jonathan Arnold A. P., I. Bottoli, Andrej Skerjanec, David Floch, A. Groenewegen, Suzanne Maahs, Claire Owen, Ieuan Jones, Philip J. Lowe

    Almmustuhtton 2014
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  3. 3
    Assessment of the anti-CD40 antibody iscalimab in patients with primary Sjögren's syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study

    Assessment of the anti-CD40 antibody iscalimab in patients with primary Sjögren's syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study Dahkki Benjamin A. Fisher, Antónia Szántó, Wan‐Fai Ng, Stefano Bombardieri, Maximilian Posch, Athena Papas, Arwa M. Farag, Thomas Daikeler, Bettina Bannert, Diego Kyburz, Alan Kivitz, Steven E. Carsons, David Isenberg, Francesca Barone, Simon Bowman, Pascal Espié, David Floch, Cyrielle Dupuy, Xiaohui Ren, P. Faerber, A. Wright, Hans Hockey, Michael Rotte, Julie Milojevic, Alexandre Avraméas, Marie‐Anne Valentin, James S. Rush, P Gergely

    Almmustuhtton 2020
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:

Ohcanreaiddut: